Gene symbol: ORM2

Also known as: AGP2; AGP-B; AGP-B'

Organism: Homo sapiens

Summary: This gene encodes a key acute phase plasma protein. Because of its increase due to acute inflammation, this protein is classified as an acute-phase reactant. The specific function of this protein has not yet been determined; however, it may be involved in aspects of immunosuppression. [provided by RefSeq, Jul 2008]

NCBI gene ID: 5005 Ensembl:ENSG00000228278 MIM:138610 AllianceGenome:HGNC:8499


GO Annotation


Category Term ID Term description
Process GO:0001817 Regulation of cytokine production
Process GO:0001819 Positive regulation of cytokine production
Process GO:0002526 Acute inflammatory response
Process GO:0002682 Regulation of immune system process
Process GO:0006950 Response to stress
Process GO:0006952 Defense response
Process GO:0006953 Acute-phase response
Process GO:0006954 Inflammatory response
Process GO:0009893 Positive regulation of metabolic process
Process GO:0010468 Regulation of gene expression
Process GO:0010604 Positive regulation of macromolecule metabolic process
Process GO:0010628 Positive regulation of gene expression
Process GO:0019222 Regulation of metabolic process
Process GO:0032651 Regulation of interleukin-1 beta production
Process GO:0032652 Regulation of interleukin-1 production
Process GO:0032680 Regulation of tumor necrosis factor production
Process GO:0032731 Positive regulation of interleukin-1 beta production
Process GO:0032732 Positive regulation of interleukin-1 production
Process GO:0032760 Positive regulation of tumor necrosis factor production
Process GO:0048518 Positive regulation of biological process
Process GO:0050789 Regulation of biological process
Process GO:0050896 Response to stimulus
Process GO:0051239 Regulation of multicellular organismal process
Process GO:0051240 Positive regulation of multicellular organismal process
Process GO:0060255 Regulation of macromolecule metabolic process
Process GO:0065007 Biological regulation
Process GO:1903555 Regulation of tumor necrosis factor superfamily cytokine production
Process GO:1903557 Positive regulation of tumor necrosis factor superfamily cytokine production
Component GO:0000323 Lytic vacuole
Component GO:0005576 Extracellular region
Component GO:0005615 Extracellular space
Component GO:0005622 Intracellular anatomical structure
Component GO:0005737 Cytoplasm
Component GO:0005764 Lysosome
Component GO:0005766 Primary lysosome
Component GO:0005773 Vacuole
Component GO:0005775 Vacuolar lumen
Component GO:0012505 Endomembrane system
Component GO:0030141 Secretory granule
Component GO:0030312 External encapsulating structure
Component GO:0031012 Extracellular matrix
Component GO:0031091 Platelet alpha granule
Component GO:0031093 Platelet alpha granule lumen
Component GO:0031410 Cytoplasmic vesicle
Component GO:0031974 Membrane-enclosed lumen
Component GO:0031982 Vesicle
Component GO:0031983 Vesicle lumen
Component GO:0034774 Secretory granule lumen
Component GO:0035578 Azurophil granule lumen
Component GO:0035580 Specific granule lumen
Component GO:0042581 Specific granule
Component GO:0042582 Azurophil granule
Component GO:0043226 Organelle
Component GO:0043227 Membrane-bounded organelle
Component GO:0043229 Intracellular organelle
Component GO:0043230 Extracellular organelle
Component GO:0043231 Intracellular membrane-bounded organelle
Component GO:0043233 Organelle lumen
Component GO:0060205 Cytoplasmic vesicle lumen
Component GO:0062023 Collagen-containing extracellular matrix
Component GO:0065010 Extracellular membrane-bounded organelle
Component GO:0070013 Intracellular organelle lumen
Component GO:0070062 Extracellular exosome
Component GO:0071944 Cell periphery
Component GO:0072562 Blood microparticle
Component GO:0097708 Intracellular vesicle
Component GO:0099503 Secretory vesicle
Component GO:0110165 Cellular anatomical entity
Component GO:1903561 Extracellular vesicle

Pathway annotation


Category Term ID Term description
RCTM HSA-109582 Hemostasis
RCTM HSA-114608 Platelet degranulation
RCTM HSA-168249 Innate Immune System
RCTM HSA-168256 Immune System
RCTM HSA-6798695 Neutrophil degranulation
RCTM HSA-76002 Platelet activation, signaling and aggregation
RCTM HSA-76005 Response to elevated platelet cytosolic Ca2+
WikiPathways WP2877 Vitamin D receptor pathway

Expression profile of ORM2 in omics data



ID GSE120596
Title Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction is Associated with Differences in Activation of the Cyclooxygenase Pathway
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM3405450 1001_baseline cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: baseline library barcode: ATTACTCG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405451 1001_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: post-surgery 1 library barcode: TCCGGAGA-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405452 1002_baseline cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: baseline library barcode: CGCTCATT-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405453 1002_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: post-surgery 1 library barcode: GAGATTCC-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405454 1003_baseline cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: baseline library barcode: ATTCAGAA-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405455 1003_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: post-surgery 1 library barcode: GAATTCGT-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405456 1004_baseline cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: baseline library barcode: CTGAAGCT-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405457 1004_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: post-surgery 1 library barcode: TAATGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder
GSM3405458 1005_baseline cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: baseline library barcode: CGGCTATG-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405459 1005_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-TATAGCCT drug treatment: Placebo response group: Placebo
GSM3405460 1006_baseline cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: baseline library barcode: TCTCGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 2.0
GSM3405461 1006_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: post-surgery 1 library barcode: AGCGATAG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405462 1007_baseline cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: baseline library barcode: ATTACTCG-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405463 1007_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: post-surgery 1 library barcode: TCCGGAGA-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405464 1008_baseline cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: baseline library barcode: CGCTCATT-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405465 1008_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405466 1008_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405467 1011_baseline cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: baseline library barcode: GAATTCGT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405468 1011_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405469 1011_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405470 1012_baseline cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: baseline library barcode: CGGCTATG-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405471 1012_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405472 1012_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder
GSM3405473 1014_baseline cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: baseline library barcode: AGCGATAG-ATAGAGGC drug treatment: Placebo response group: Placebo 0.0
GSM3405474 1014_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405475 1014_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405476 1015_baseline cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: baseline library barcode: CGCTCATT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405477 1015_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 3.0
GSM3405478 1015_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405479 1016_baseline cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: baseline library barcode: GAATTCGT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405480 1016_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405481 1016_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405482 1017_baseline cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: baseline library barcode: CGGCTATG-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405483 1017_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405484 1017_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 2 library barcode: TCTCGCGC-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405485 1018_baseline cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: baseline library barcode: AGCGATAG-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405486 1018_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405487 1018_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405488 1019_baseline cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: baseline library barcode: CGCTCATT-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405489 1019_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405490 1019_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 1.0
GSM3405491 1020_baseline cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: baseline library barcode: GAATTCGT-GGCTCTGA drug treatment: Placebo response group: Placebo
GSM3405492 1020_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-GGCTCTGA drug treatment: Placebo response group: Placebo 0.0
GSM3405493 1020_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-GGCTCTGA drug treatment: Placebo response group: Placebo 0.0
GSM3405494 1021_baseline cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: baseline library barcode: CGGCTATG-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405495 1021_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 2.0
GSM3405496 1021_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405497 1022_baseline cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: baseline library barcode: AGCGATAG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405498 1022_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405499 1022_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405500 1023_baseline cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: baseline library barcode: CGCTCATT-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405501 1023_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405502 1023_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405503 1024_baseline cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: baseline library barcode: GAATTCGT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405504 1024_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405505 1024_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405506 1026_baseline cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: baseline library barcode: CGGCTATG-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405507 1026_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 2.0
GSM3405508 1026_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-AGGCGAAG drug treatment: Placebo response group: Placebo 4.0
GSM3405509 1027_baseline cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: baseline library barcode: AGCGATAG-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405510 1027_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405511 1027_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405512 1028_baseline cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: baseline library barcode: CGCTCATT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405513 1028_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405514 1028_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405515 1029_baseline cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: baseline library barcode: GAATTCGT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405516 1029_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 3.0
GSM3405517 1029_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405518 1030_baseline cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: baseline library barcode: CGGCTATG-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405519 1030_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405520 1030_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405521 1032_baseline cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: baseline library barcode: AGCGATAG-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405522 1032_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-CAGGACGT drug treatment: Placebo response group: Placebo 0.0
GSM3405523 1032_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-CAGGACGT drug treatment: Placebo response group: Placebo 0.0
GSM3405524 1033_baseline cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: baseline library barcode: CGCTCATT-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405525 1033_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405526 1033_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0

ID GSE150408
Title Identification of key genes potentially related to intervertebral disc degeneration by microarray analysis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM4548691 volunteer-9 tissue: whole blood diagnosis: healthy control treatment: n/a 7.536020353
GSM4548692 volunteer-10 tissue: whole blood diagnosis: healthy control treatment: n/a 5.629557033
GSM4548693 volunteer-11 tissue: whole blood diagnosis: healthy control treatment: n/a 5.046849222
GSM4548694 volunteer-12 tissue: whole blood diagnosis: healthy control treatment: n/a 4.677666744
GSM4548695 volunteer-13 tissue: whole blood diagnosis: healthy control treatment: n/a 6.388293214
GSM4548696 volunteer-14 tissue: whole blood diagnosis: healthy control treatment: n/a 5.810068345
GSM4548697 volunteer-15 tissue: whole blood diagnosis: healthy control treatment: n/a 5.38956477
GSM4548698 volunteer-16 tissue: whole blood diagnosis: healthy control treatment: n/a 5.525005259
GSM4548699 volunteer-17 tissue: whole blood diagnosis: healthy control treatment: n/a 7.269213996
GSM4548700 volunteer-18 tissue: whole blood diagnosis: healthy control treatment: n/a 5.579937533
GSM4548701 volunteer-19 tissue: whole blood diagnosis: healthy control treatment: n/a 5.91796023
GSM4548702 volunteer-20 tissue: whole blood diagnosis: healthy control treatment: n/a 6.353479723
GSM4548703 volunteer-21 tissue: whole blood diagnosis: healthy control treatment: n/a 6.721702684
GSM4548704 volunteer-22 tissue: whole blood diagnosis: healthy control treatment: n/a 6.429471683
GSM4548705 volunteer-23 tissue: whole blood diagnosis: healthy control treatment: n/a 6.009062063
GSM4548706 volunteer-24 tissue: whole blood diagnosis: healthy control treatment: n/a 6.058006176
GSM4548707 volunteer-25 tissue: whole blood diagnosis: healthy control treatment: n/a 6.26672806
GSM4548708 patient-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 5.157863711
GSM4548709 patient-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 5.300699594
GSM4548710 patient-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 7.424273526
GSM4548711 patient-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 6.862882243
GSM4548712 patient-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.699448252
GSM4548713 patient-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 8.707031099
GSM4548714 patient-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 6.678201443
GSM4548715 patient-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.882455984
GSM4548716 patient-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 7.39487597
GSM4548717 patient-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 5.320452223
GSM4548718 patient-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.935943105
GSM4548719 patient-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 6.32073013
GSM4548720 patient-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 6.934295798
GSM4548721 patient-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 5.282217873
GSM4548722 patient-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 6.916771118
GSM4548723 patient-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 7.256856333
GSM4548724 patient-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 6.078239878
GSM4548725 treatment-1 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.175571312
GSM4548726 treatment-2 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.048913336
GSM4548727 treatment-3 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 7.684119909
GSM4548728 treatment-4 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.987425538
GSM4548729 treatment-5 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.520300581
GSM4548730 treatment-6 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 8.233696612
GSM4548731 treatment-7 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.220320285
GSM4548732 treatment-8 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.644941642
GSM4548733 treatment-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.06305337
GSM4548734 treatment-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.617826724
GSM4548735 treatment-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.951362086
GSM4548736 treatment-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.140419682
GSM4548737 treatment-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.769108051
GSM4548738 treatment-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.578204615
GSM4548739 treatment-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.429731083
GSM4548740 treatment-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 7.545795909
GSM4548741 treatment-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.67699402
GSM4548742 treatment-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.77980436
GSM4548743 treatment-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.377203838
GSM4548744 treatment-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.258539769
GSM4548745 treatment-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 7.638683317
GSM4548746 treatment-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.885361821
GSM4548747 treatment-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.444908713
GSM4548748 treatment-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.039372599
GSM4548749 treatment-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.778255908

ID GSE166193
Title Expression data from human astrocytes (HA) under oxygen-glucose deprivation / reoxygenation
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5065655 without DEX pretreatment, reoxygenation time is 0 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 0 h tissue: brain 2.94019
GSM5065656 without DEX pretreatment, reoxygenation time is 2 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 2 h tissue: brain 3.83835
GSM5065657 without DEX pretreatment, reoxygenation time is 6 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 6 h tissue: brain 3.49455
GSM5065658 without DEX pretreatment, reoxygenation time is 12 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 12 h tissue: brain 4.05303
GSM5065659 without DEX pretreatment, reoxygenation time is 24 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 24 h tissue: brain 4.69025
GSM5065660 with DEX pretreatment, reoxygenation time is 0 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 0 h tissue: brain 3.7353
GSM5065661 with DEX pretreatment, reoxygenation time is 2 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 2 h tissue: brain 3.45374
GSM5065662 with DEX pretreatment, reoxygenation time is 6 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 6 h tissue: brain 2.2806
GSM5065663 with DEX pretreatment, reoxygenation time is 12 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 12 h tissue: brain 4.3499
GSM5065664 with DEX pretreatment, reoxygenation time is 24 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 24 h tissue: brain 4.41145
GSM5065665 control cell type: astrocyte treatment: without stress tissue: brain 3.35569

ID GSE179004
Title Expression data from glioblastoma surgical specimens
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5403447 glioblastoma tissue 1 in TIVA group tissue: glioblastoma 1.521236527
GSM5403448 glioblastoma tissue 2 in TIVA group tissue: glioblastoma 1.045808289
GSM5403449 glioblastoma tissue 3 in TIVA group tissue: glioblastoma 1.894033922
GSM5403450 glioblastoma tissue 1 in INHA group tissue: glioblastoma 1.444383878
GSM5403451 glioblastoma tissue 2 in INHA group tissue: glioblastoma 2.310095467
GSM5403452 glioblastoma tissue 3 in INHA group tissue: glioblastoma 1.008520825

ID GSE212044
Title Reversibility of etomidate-induced contractile arrest through activation of myocardial autophagy
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM6508421 IPSC-CM cells, DSMO 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 1.0
GSM6508422 IPSC-CM cells, DSMO 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 4.0
GSM6508423 IPSC-CM cells, DSMO 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 0.0
GSM6508424 IPSC-CM cells, Etomidate 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 0.0
GSM6508425 IPSC-CM cells, Etomidate 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 4.0
GSM6508426 IPSC-CM cells, Etomidate 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 5.0
GSM6508427 IPSC-CM cells, Propofol 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 0.0
GSM6508428 IPSC-CM cells, Propofol 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 0.0
GSM6508429 IPSC-CM cells, Propofol 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 5.0

ID GSE255952
Title Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM8083291 patient C1P1, before first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 3.09356
GSM8083292 patient C1P1, after first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 4.22532
GSM8083293 patient C1P1, before second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 3.34312
GSM8083294 patient C1P1, after second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 3.9458
GSM8083295 patient C1P2, before first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.1925
GSM8083296 patient C1P2, after first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.28229
GSM8083297 patient C1P2, before first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.48209
GSM8083298 patient C1P2, after first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.41039
GSM8083299 patient C1P3, before first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.18398
GSM8083300 patient C1P3, after first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.15093
GSM8083301 patient C1P3, before first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.52535
GSM8083302 patient C1P3, after first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.3609
GSM8083303 patient C1P3, before second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp 3.52525
GSM8083304 patient C1P3, after second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none 3.7287
GSM8083305 patient C1P4, before first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.24957
GSM8083306 patient C1P4, after first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.76539
GSM8083307 patient C1P4, before first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.66382
GSM8083308 patient C1P4, after first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.57608
GSM8083309 patient C1P5, before first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.13151
GSM8083310 patient C1P5, after first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.33372
GSM8083311 patient C1P5, before second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 3.50625
GSM8083312 patient C1P5, after second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 3.30641
GSM8083313 patient C2P1, before first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.44781
GSM8083314 patient C2P1, after first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.64952
GSM8083315 patient C2P1, before first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.05496
GSM8083316 patient C2P1, after first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.82466
GSM8083317 patient C2P2, before first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.60413
GSM8083318 patient C2P2, after first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 5.09187
GSM8083319 patient C2P3, before first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.40404
GSM8083320 patient C2P3, after first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.12011
GSM8083321 patient C2P3, before first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.77781
GSM8083322 patient C2P3, after first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.57839
GSM8083323 patient C2P4, before first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.36648
GSM8083324 patient C2P4, after first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.90496
GSM8083325 patient C2P5, before first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.90872
GSM8083326 patient C2P5, after first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.27943
GSM8083327 patient C2P6, before first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.30484
GSM8083328 patient C2P6, after first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.04954
GSM8083329 patient C2P7, before first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 3.04285
GSM8083330 patient C2P7, after first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 3.43917
GSM8083331 patient C2P8, before first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.22042
GSM8083332 patient C2P8, after first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.29817
GSM8083333 patient C3P1, before second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 3.45668
GSM8083334 patient C3P1, after second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 3.61241
GSM8083335 patient C4P1, before first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 3.89848
GSM8083336 patient C4P1, after first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 3.55906
GSM8083337 patient C4P2, before first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.32618
GSM8083338 patient C4P2, after first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 2.99372

ID GSE56256
Title Influence of hexafluoro-2-propanol (HFIP) on lipopolysaccharides-induced inflammation in human microvascular endothelial cells of the lung
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM1357752 7_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 9.435103999999999
GSM1357753 8_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 37.613375
GSM1357754 9_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 7.2581685
GSM1357755 4_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 5.037208
GSM1357756 5_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 118.77754999999999
GSM1357757 6_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 6.1428709999999995
GSM1357758 11_LPS-HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs 5.4185300000000005
GSM1357759 12_LPS-HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs 6.87129
GSM1357760 1_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 8.731637
GSM1357761 2_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 7.19782
GSM1357762 3_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 5.677994